You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClemastine
Accession NumberDB00283  (APRD00875)
TypeSmall Molecule
GroupsApproved
DescriptionAn ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. [PubChem]
Structure
Thumb
Synonyms
(+)-(2R)-2-(2-(((R)-P-chloro-alpha-Methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
(+)-(2R)-2-[2-[[(R)-P-chloro-alpha-Methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
Clemastina
Clemastine
Clemastinum
Meclastin
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clemastine Fumaratetablet2.68 mg/1oralTeva Pharmaceuticals USA Inc1992-04-01Not applicableUs
Clemastine Fumaratesyrup.5 mg/mLoralSilarx Pharmaceuticals, Inc1997-12-17Not applicableUs
Clemastine Fumaratesyrup.5 mg/mLoralQualitest Pharmaceuticals, Inc1997-12-17Not applicableUs
Clemastine Fumaratetablet2.68 mg/1oralSandoz Inc1993-10-31Not applicableUs
Clemastine Fumaratetablet2.68 mg/1oralNorthwind Pharmaceuticals, LLC2014-04-28Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Allergy Relieftablet1.34 mg/1oralCVS Pharmacy1996-08-28Not applicableUs
Clemastine Fumaratetablet1.34 mg/1oralPhysicians Total Care, Inc.2008-06-27Not applicableUs
Clemastine Fumaratetablet1.34 mg/1oralSandoz Inc1993-10-312016-10-31Us
Clemastine Fumaratetablet1.34 mg/1oralCarilion Materials Management1993-10-31Not applicableUs
Dayhist Allergytablet1.34 mg/1oralH E B1995-08-30Not applicableUs
Dayhist Allergytablet1.34 mg/1oralPublix Super Markets Inc1996-11-20Not applicableUs
Dayhist Allergytablet1.34 mg/1oralHy Vee Inc1996-06-21Not applicableUs
Dayhist Allergy 12 Hour Relieftablet1.34 mg/1oralKroger Company1996-08-07Not applicableUs
Good Neighbor Pharmacy Dayhist Allergytablet1.34 mg/1oralAmerisource Bergen1996-06-28Not applicableUs
Good Sense Dayhist Allergytablet1.34 mg/1oralL Perrigo Company1996-07-11Not applicableUs
Leader Allerhisttablet1.34 mg/1oralCardinal Health1997-09-30Not applicableUs
Sunmark 12 Hour Allergy Relieftablet1.34 mg/1oralMc Kesson2003-07-03Not applicableUs
Tavist Allergytablet1.34 mg/1oralNovartis Consumer Health, Inc.2010-01-01Not applicableUs
Tavist Tablets 1mgtablet1 mgoralNovartis Consumer Health Canada Inc.1997-05-202014-07-23Canada
Topcare Dayhist Allergytablet1.34 mg/1oralTopco Associates LLC1996-07-23Not applicableUs
Wal Histtablet1.34 mg/1oralWalgreen Company1996-05-31Not applicableUs
Wal Hist 12 Hour Relieftablet1.34 mg/1oralWalgreen Company1996-05-31Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
AgastenNovartis (Brazil)
Allerhist-1Not Available
TavegilNovartis
TavegylNovartis
TavistNovartis
Tavist-1Novartis
Brand mixtures
NameLabellerIngredients
Tavist-D TabletsNovartis Consumer Health Canada Inc.
Salts
Name/CASStructureProperties
Clemastine fumarate
ThumbNot applicableDBSALT000901
Categories
UNII95QN29S1ID
CAS number15686-51-8
WeightAverage: 343.89
Monoisotopic: 343.170292166
Chemical FormulaC21H26ClNO
InChI KeyInChIKey=YNNUSGIPVFPVBX-NHCUHLMSSA-N
InChI
InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
IUPAC Name
(2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine
SMILES
CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Benzylether
  • Halobenzene
  • Chlorobenzene
  • N-alkylpyrrolidine
  • Aryl halide
  • Aryl chloride
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold.
PharmacodynamicsClemastine is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines competitively antagonize various physiological effects of histamine including increased capillary permeability and dilatation, the formation of edema, the "flare" and "itch" response, and gastrointestinal and respiratory smooth muscle constriction. Within the vascular tree, H1- receptor antagonists inhibit both the vasoconstrictor and vasodilator effects of histamine. Depending on the dose, H1- receptor antagonists can produce CNS stimulation or depression. Most antihistamines exhibit central and/or peripheral anticholinergic activity. Antihistamines act by competitively blocking H1- receptor sites. Antihistamines do not pharmacologically antagonize or chemically inactivate histamine, nor do they prevent the release of histamine.
Mechanism of actionClemastine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Related Articles
AbsorptionRapidly absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Antihistamines appear to be metabolized in the liver chiefly via mono- and didemethylation and glucuronide conjugation.

Route of eliminationUrinary excretion is the major mode of elimination.
Half lifeNot Available
ClearanceNot Available
ToxicityOral LD50 in rat and mouse is 3550 mg/kg and 730 mg/kg, respectively. Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. In children, stimulation predominates initially in a syndrome which may include excitement, hallucinations, ataxia, incoordination, muscle twitching, athetosis, hyperthermia, cyanosis convulsions, tremors, and hyperreflexia followed by postictal depression and cardio-respiratory arrest. Convulsions in children may be preceded by mild depression. Dry mouth, fixed dilated pupils, flushing of the face, and fever are common. In adults, CNS depression, ranging from drowsiness to coma, is more common.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9942
Blood Brain Barrier+0.9918
Caco-2 permeable+0.6652
P-glycoprotein substrateSubstrate0.6659
P-glycoprotein inhibitor IInhibitor0.808
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.8471
CYP450 2C9 substrateNon-substrate0.819
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7176
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7028
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.7454
CarcinogenicityNon-carcinogens0.8549
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.9450 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5986
hERG inhibition (predictor II)Inhibitor0.8702
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis mid atlantic llc
  • Novex pharma
  • Silarx pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Wockhardt eu operations (swiss) ag
  • Novartis pharmaceuticals corp
  • Perrigo co
  • Sandoz inc
Packagers
Dosage forms
FormRouteStrength
Syruporal.5 mg/mL
Tabletoral2.68 mg/1
Tabletoral1.34 mg/1
Tabletoral1 mg
Tablet (extended-release)oral
Prices
Unit descriptionCostUnit
Clemastine fumarate powder255.0USD g
Clemastine Fumarate 0.67 mg/5ml Syrup 120ml Bottle22.2USD bottle
Clemastine Fumarate 2.68 mg tablet0.9USD tablet
Clemastine fum 2.68 mg tablet0.86USD tablet
Tavist nd 10 mg tablet0.74USD tablet
Clemastine fum 1.34 mg tablet0.58USD tablet
Tavist-1 1.34 mg tablet0.5USD tablet
Clemastine Fumarate 1.34 mg tablet0.34USD tablet
Dayhist tablet0.31USD tablet
CVS Pharmacy dayhist allergy tablet0.28USD tablet
Dayhist-1 1.34 mg tablet0.25USD tablet
Tavist max-str sinus caplet0.17USD caplet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point178 °C (hydrogen fumarate formulation)Not Available
water solubilitySoluble (hydrogen fumarate formulation)Not Available
logP5.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000405 mg/mLALOGPS
logP5.29ALOGPS
logP4.92ChemAxon
logS-5.9ALOGPS
pKa (Strongest Basic)9.55ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity101.65 m3·mol-1ChemAxon
Polarizability39.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

British Patent 942,152; November 20,1963; assigned to Sandoz Ltd.

General References
  1. Hayashi H, Okajima M, Yamada K: Atrial T (Ta) loop in dogs with or without atrial injury. Am Heart J. 1976 May;91(5):607-17. [PubMed:1266718 ]
  2. Schran HF, Petryk L, Chang CT, O'Connor R, Gelbert MB: The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol. 1996 Oct;36(10):911-22. [PubMed:8930778 ]
External Links
ATC CodesD04AA14R06AA04R06AA54
AHFS Codes
  • 04:04.04
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.2 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Clemastine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Clemastine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Clemastine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clemastine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the anticholinergic activities of Clemastine.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Clemastine.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Clemastine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clemastine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clemastine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Clemastine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Clemastine.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Clemastine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Clemastine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clemastine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Clemastine.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Clemastine.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Clemastine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clemastine.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Clemastine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Clemastine.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Clemastine.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Clemastine.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Clemastine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Clemastine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Clemastine.
AlosetronThe metabolism of Alosetron can be decreased when combined with Clemastine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Clemastine.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Clemastine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clemastine.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Clemastine.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Clemastine.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Clemastine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Clemastine.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Clemastine.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Clemastine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clemastine.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Clemastine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clemastine.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Clemastine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clemastine.
AmoxapineThe risk or severity of adverse effects can be increased when Clemastine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Clemastine.
AmphetamineAmphetamine may decrease the sedative activities of Clemastine.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Clemastine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Clemastine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Clemastine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Clemastine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Clemastine.
ApremilastThe metabolism of Apremilast can be decreased when combined with Clemastine.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Clemastine.
AprindineThe metabolism of Aprindine can be decreased when combined with Clemastine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Clemastine.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Clemastine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Clemastine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clemastine.
ArtemetherThe metabolism of Artemether can be decreased when combined with Clemastine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Clemastine.
AsenapineThe metabolism of Asenapine can be decreased when combined with Clemastine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clemastine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Clemastine.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Clemastine.
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Clemastine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Clemastine.
AvanafilThe metabolism of Avanafil can be decreased when combined with Clemastine.
AxitinibThe metabolism of Axitinib can be decreased when combined with Clemastine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Clemastine.
AzelastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clemastine.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Clemastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Clemastine.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Clemastine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Clemastine.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Clemastine.
BenmoxinBenmoxin may increase the anticholinergic activities of Clemastine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Clemastine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Clemastine.
BenzphetamineBenzphetamine may decrease the sedative activities of Clemastine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Clemastine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Clemastine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clemastine.
Benzylpenicilloyl PolylysineClemastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BepridilThe metabolism of Bepridil can be decreased when combined with Clemastine.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Clemastine.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Clemastine.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Clemastine.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Clemastine.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Clemastine.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Clemastine.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Clemastine.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Clemastine.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Clemastine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Clemastine.
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Clemastine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Clemastine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Clemastine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
BrimonidineThe risk or severity of adverse effects can be increased when Clemastine is combined with Brimonidine.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Clemastine.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Clemastine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clemastine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Clemastine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Clemastine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clemastine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Clemastine.
BudesonideThe metabolism of Budesonide can be decreased when combined with Clemastine.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Clemastine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Clemastine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clemastine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Clemastine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Clemastine.
BupropionThe metabolism of Bupropion can be decreased when combined with Clemastine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Clemastine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clemastine.
BusulfanThe metabolism of Busulfan can be decreased when combined with Clemastine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Clemastine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Clemastine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Clemastine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Clemastine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clemastine.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Clemastine.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Clemastine.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Clemastine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Clemastine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Clemastine.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Clemastine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Clemastine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Clemastine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clemastine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Clemastine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clemastine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Clemastine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Clemastine.
CarisoprodolThe risk or severity of adverse effects can be increased when Clemastine is combined with Carisoprodol.
CaroxazoneCaroxazone may increase the anticholinergic activities of Clemastine.
CarteololThe metabolism of Carteolol can be decreased when combined with Clemastine.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Clemastine.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Clemastine.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Clemastine.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Clemastine.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Clemastine.
CetirizineThe risk or severity of adverse effects can be increased when Clemastine is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Clemastine.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Clemastine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clemastine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Clemastine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clemastine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Clemastine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clemastine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Clemastine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Clemastine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Clemastine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Clemastine.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Clemastine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clemastine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clemastine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Clemastine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clemastine.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Clemastine.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Clemastine.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Clemastine.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Clemastine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clemastine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Clemastine.
CisaprideThe metabolism of Cisapride can be decreased when combined with Clemastine.
CitalopramThe risk or severity of adverse effects can be increased when Clemastine is combined with Citalopram.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clemastine is combined with Clidinium.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Clemastine.
ClobazamThe metabolism of Clobazam can be decreased when combined with Clemastine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Clemastine.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Clemastine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Clemastine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Clemastine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Clemastine.
ClomipramineThe risk or severity of adverse effects can be increased when Clemastine is combined with Clomipramine.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Clemastine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Clemastine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Clemastine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clemastine.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Clemastine.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Clemastine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clemastine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Clemastine.
ClozapineThe metabolism of Clozapine can be decreased when combined with Clemastine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Clemastine.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Clemastine.
CocaineThe metabolism of Cocaine can be decreased when combined with Clemastine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Clemastine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Clemastine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clemastine.
ColchicineThe metabolism of Colchicine can be decreased when combined with Clemastine.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Clemastine.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Clemastine.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Clemastine.
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Clemastine.
CyclizineThe risk or severity of adverse effects can be increased when Clemastine is combined with Cyclizine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Clemastine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clemastine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Clemastine.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Clemastine.
CyproheptadineThe risk or severity of adverse effects can be increased when Clemastine is combined with Cyproheptadine.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Clemastine.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Clemastine.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Clemastine.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Clemastine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Clemastine.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Clemastine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clemastine.
DapoxetineThe risk or severity of adverse effects can be increased when Clemastine is combined with Dapoxetine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Clemastine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Clemastine.
DarunavirThe metabolism of Darunavir can be decreased when combined with Clemastine.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Clemastine.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Clemastine.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Clemastine.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Clemastine.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Clemastine.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Clemastine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Clemastine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clemastine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Clemastine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Clemastine.
DesloratadineThe risk or severity of adverse effects can be increased when Clemastine is combined with Desloratadine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Clemastine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Clemastine.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Clemastine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Clemastine is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Clemastine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clemastine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Clemastine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Clemastine.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Clemastine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Clemastine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clemastine.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Clemastine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clemastine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Clemastine.
DiazepamThe metabolism of Diazepam can be decreased when combined with Clemastine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clemastine.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Clemastine.
DifenoxinThe risk or severity of adverse effects can be increased when Clemastine is combined with Difenoxin.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Clemastine.
DigoxinThe metabolism of Digoxin can be decreased when combined with Clemastine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Clemastine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clemastine.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Clemastine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clemastine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clemastine.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Clemastine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Clemastine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Clemastine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clemastine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clemastine.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Clemastine.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Clemastine.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Clemastine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Clemastine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Clemastine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Clemastine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Clemastine.
DopamineThe metabolism of Dopamine can be decreased when combined with Clemastine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Clemastine.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Clemastine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Clemastine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Clemastine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Clemastine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Clemastine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
DoxylamineThe risk or severity of adverse effects can be increased when Clemastine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Clemastine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Clemastine.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Clemastine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Clemastine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Clemastine.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Clemastine.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Clemastine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clemastine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Clemastine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Clemastine.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Clemastine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clemastine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Clemastine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Clemastine.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Clemastine.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Clemastine.
EncainideThe metabolism of Encainide can be decreased when combined with Clemastine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Clemastine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clemastine.
EntacaponeThe risk or severity of adverse effects can be increased when Clemastine is combined with Entacapone.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Clemastine.
EpinastineThe metabolism of Epinastine can be decreased when combined with Clemastine.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Clemastine.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Clemastine.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Clemastine.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Clemastine.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Clemastine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Clemastine.
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Clemastine.
EscitalopramThe risk or severity of adverse effects can be increased when Clemastine is combined with Escitalopram.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Clemastine.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Clemastine.
EstazolamThe metabolism of Estazolam can be decreased when combined with Clemastine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clemastine.
EstradiolThe metabolism of Estradiol can be decreased when combined with Clemastine.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Clemastine.
EstramustineThe metabolism of Estramustine can be decreased when combined with Clemastine.
EstroneThe metabolism of Estrone can be decreased when combined with Clemastine.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Clemastine.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Clemastine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clemastine.
EthanolClemastine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Clemastine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Clemastine.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Clemastine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clemastine.
EthotoinThe risk or severity of adverse effects can be increased when Clemastine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clemastine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clemastine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Clemastine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clemastine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Clemastine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Clemastine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Clemastine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clemastine.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Clemastine.
EtoperidoneThe risk or severity of adverse effects can be increased when Clemastine is combined with Etoperidone.
EtoposideThe metabolism of Etoposide can be decreased when combined with Clemastine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Clemastine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Clemastine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Clemastine.
EverolimusThe metabolism of Everolimus can be decreased when combined with Clemastine.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Clemastine.
EzogabineThe risk or severity of adverse effects can be increased when Clemastine is combined with Ezogabine.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Clemastine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Clemastine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Clemastine.
FelodipineThe metabolism of Felodipine can be decreased when combined with Clemastine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clemastine.
FenfluramineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fenfluramine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Clemastine.
FentanylThe metabolism of Fentanyl can be decreased when combined with Clemastine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clemastine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clemastine.
FexofenadineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fexofenadine.
FinasterideThe metabolism of Finasteride can be decreased when combined with Clemastine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Clemastine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Clemastine.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Clemastine.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Clemastine.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clemastine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Clemastine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Clemastine.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Clemastine.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Clemastine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clemastine.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Clemastine.
FluoxetineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clemastine.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Clemastine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clemastine.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Clemastine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clemastine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clemastine.
FlutamideThe metabolism of Flutamide can be decreased when combined with Clemastine.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Clemastine.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Clemastine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Clemastine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Clemastine.
FluvoxamineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Clemastine.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Clemastine.
FosphenytoinThe risk or severity of adverse effects can be increased when Clemastine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clemastine.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Clemastine.
FurazolidoneFurazolidone may increase the anticholinergic activities of Clemastine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clemastine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Clemastine is combined with gabapentin enacarbil.
GalantamineThe metabolism of Galantamine can be decreased when combined with Clemastine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Clemastine.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Clemastine.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Clemastine.
GlipizideThe metabolism of Glipizide can be decreased when combined with Clemastine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Clemastine.
GlyburideThe metabolism of Glyburide can be decreased when combined with Clemastine.
GranisetronThe metabolism of Granisetron can be decreased when combined with Clemastine.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Clemastine.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Clemastine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clemastine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Clemastine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Clemastine.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Clemastine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clemastine.
HalothaneThe metabolism of Halothane can be decreased when combined with Clemastine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clemastine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Clemastine.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Clemastine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clemastine.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Clemastine.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clemastine.
HydracarbazineHydracarbazine may increase the anticholinergic activities of Clemastine.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Clemastine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clemastine.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Clemastine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Clemastine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clemastine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Clemastine.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Clemastine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
HydroxyzineThe risk or severity of adverse effects can be increased when Clemastine is combined with Hydroxyzine.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Clemastine.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Clemastine.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Clemastine resulting in a loss in efficacy.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Clemastine.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Clemastine.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Clemastine.
ImipramineThe metabolism of Imipramine can be decreased when combined with Clemastine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clemastine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Clemastine.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Clemastine.
IndalpineThe risk or severity of adverse effects can be increased when Clemastine is combined with Indalpine.
IndapamideThe metabolism of Indapamide can be decreased when combined with Clemastine.
IndinavirThe metabolism of Indinavir can be decreased when combined with Clemastine.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Clemastine.
IproclozideIproclozide may increase the anticholinergic activities of Clemastine.
IproniazidIproniazid may increase the anticholinergic activities of Clemastine.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Clemastine.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Clemastine.
IsocarboxazidIsocarboxazid may increase the anticholinergic activities of Clemastine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clemastine.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clemastine.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Clemastine.
IsradipineThe metabolism of Isradipine can be decreased when combined with Clemastine.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Clemastine.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Clemastine.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Clemastine.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Clemastine.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Clemastine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Clemastine.
KetamineThe metabolism of Ketamine can be decreased when combined with Clemastine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clemastine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Clemastine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clemastine.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Clemastine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clemastine.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Clemastine.
LabetalolThe metabolism of Labetalol can be decreased when combined with Clemastine.
LamotrigineThe risk or severity of adverse effects can be increased when Clemastine is combined with Lamotrigine.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Clemastine.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Clemastine.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Clemastine.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Clemastine.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Clemastine.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Clemastine.
LevetiracetamThe risk or severity of adverse effects can be increased when Clemastine is combined with Levetiracetam.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Clemastine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clemastine.
LevocabastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Levocabastine.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Clemastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Clemastine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Clemastine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Clemastine.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Clemastine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clemastine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Clemastine is combined with Levomilnacipran.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Clemastine.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clemastine.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Clemastine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Clemastine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clemastine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Clemastine.
LisurideThe metabolism of Lisuride can be decreased when combined with Clemastine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Clemastine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Clemastine.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Clemastine.
LomustineThe metabolism of Lomustine can be decreased when combined with Clemastine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Clemastine.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Clemastine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Clemastine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Clemastine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clemastine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Clemastine.
LosartanThe metabolism of Losartan can be decreased when combined with Clemastine.
LovastatinThe metabolism of Lovastatin can be decreased when combined with Clemastine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clemastine.
Lu AA21004The risk or severity of adverse effects can be increased when Clemastine is combined with Lu AA21004.
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Clemastine.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Clemastine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clemastine.
MacitentanThe metabolism of Macitentan can be decreased when combined with Clemastine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Clemastine is combined with Magnesium Sulfate.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Clemastine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clemastine.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Clemastine.
MebanazineMebanazine may increase the anticholinergic activities of Clemastine.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Clemastine.
MeclizineThe risk or severity of adverse effects can be increased when Clemastine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Clemastine.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Clemastine.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Clemastine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Clemastine.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Clemastine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Clemastine.
MephentermineMephentermine may decrease the sedative activities of Clemastine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Clemastine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clemastine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clemastine.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Clemastine.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Clemastine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clemastine.
MetaxaloneThe risk or severity of adverse effects can be increased when Clemastine is combined with Metaxalone.
MethadoneThe metabolism of Methadone can be decreased when combined with Clemastine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Clemastine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Clemastine.
MethamphetamineMethamphetamine may decrease the sedative activities of Clemastine.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Clemastine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clemastine.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Clemastine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clemastine.
MethocarbamolThe risk or severity of adverse effects can be increased when Clemastine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clemastine.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Clemastine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Clemastine.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Clemastine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Clemastine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clemastine.
MethsuximideThe risk or severity of adverse effects can be increased when Clemastine is combined with Methsuximide.
Methylene blueMethylene blue may increase the anticholinergic activities of Clemastine.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Clemastine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clemastine.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Clemastine.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Clemastine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Clemastine.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Clemastine.
MetoprololThe metabolism of Metoprolol can be decreased when combined with Clemastine.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Clemastine.
MetyrosineClemastine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Clemastine.
MianserinThe metabolism of Mianserin can be decreased when combined with Clemastine.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Clemastine.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Clemastine.
MidazolamThe metabolism of Midazolam can be decreased when combined with Clemastine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clemastine.
MifepristoneThe metabolism of Mifepristone can be decreased when combined with Clemastine.
MilnacipranThe risk or severity of adverse effects can be increased when Clemastine is combined with Milnacipran.
MinaprineMinaprine may increase the anticholinergic activities of Clemastine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Clemastine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Clemastine.
MirtazapineClemastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clemastine.
MoclobemideMoclobemide may increase the anticholinergic activities of Clemastine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Clemastine.
ModafinilThe metabolism of Modafinil can be decreased when combined with Clemastine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Clemastine.
MontelukastThe metabolism of Montelukast can be decreased when combined with Clemastine.
MorphineThe metabolism of Morphine can be decreased when combined with Clemastine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clemastine.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Clemastine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
NabiloneThe risk or severity of adverse effects can be increased when Clemastine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clemastine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Clemastine.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Clemastine.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Clemastine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Clemastine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Clemastine.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Clemastine.
NetupitantThe metabolism of Netupitant can be decreased when combined with Clemastine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Clemastine.
NialamideNialamide may increase the anticholinergic activities of Clemastine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Clemastine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Clemastine.
NicotineThe metabolism of Nicotine can be decreased when combined with Clemastine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Clemastine.
NilotinibThe metabolism of Nilotinib can be decreased when combined with Clemastine.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Clemastine.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Clemastine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Clemastine.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Clemastine.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Clemastine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clemastine.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Clemastine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Clemastine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Clemastine.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Clemastine.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Clemastine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Clemastine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Clemastine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clemastine.
OctamoxinOctamoxin may increase the anticholinergic activities of Clemastine.
OlanzapineThe risk or severity of adverse effects can be increased when Clemastine is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Clemastine.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Clemastine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clemastine.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Clemastine.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Clemastine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clemastine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Clemastine.
OrphenadrineClemastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clemastine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Clemastine.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Clemastine.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Clemastine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clemastine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clemastine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clemastine.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Clemastine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Clemastine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clemastine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Clemastine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clemastine.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Clemastine.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Clemastine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clemastine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Clemastine.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Clemastine.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Clemastine.
ParaldehydeClemastine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Clemastine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Clemastine.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Clemastine.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Clemastine.
PargylinePargyline may increase the anticholinergic activities of Clemastine.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Clemastine.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Clemastine.
ParoxetineThe risk or severity of adverse effects can be increased when Clemastine is combined with Paroxetine.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Clemastine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Clemastine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clemastine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clemastine.
PerampanelThe metabolism of Perampanel can be decreased when combined with Clemastine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Clemastine.
PergolideThe metabolism of Pergolide can be decreased when combined with Clemastine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Clemastine.
PermethrinThe metabolism of Permethrin can be decreased when combined with Clemastine.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Clemastine.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Clemastine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clemastine.
PethidineThe metabolism of Pethidine can be decreased when combined with Clemastine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clemastine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Clemastine.
PhenelzinePhenelzine may increase the anticholinergic activities of Clemastine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Clemastine.
PheniprazinePheniprazine may increase the anticholinergic activities of Clemastine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clemastine.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Clemastine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Clemastine.
PhenoxypropazinePhenoxypropazine may increase the anticholinergic activities of Clemastine.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Clemastine.
PhenterminePhentermine may decrease the sedative activities of Clemastine.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Clemastine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clemastine.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Clemastine.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Clemastine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Clemastine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Clemastine.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Clemastine.
PindololThe metabolism of Pindolol can be decreased when combined with Clemastine.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Clemastine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clemastine.
PiperazineThe metabolism of Piperazine can be decreased when combined with Clemastine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Clemastine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Clemastine.
PirlindolePirlindole may increase the anticholinergic activities of Clemastine.
PivhydrazinePivhydrazine may increase the anticholinergic activities of Clemastine.
PizotifenThe risk or severity of adverse effects can be increased when Clemastine is combined with Pizotifen.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Clemastine.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Clemastine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clemastine.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Clemastine.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Clemastine.
PramipexoleClemastine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clemastine.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Clemastine.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Clemastine.
PrazepamThe metabolism of Prazepam can be decreased when combined with Clemastine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clemastine.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Clemastine.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Clemastine.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Clemastine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clemastine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Clemastine.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Clemastine.
PrimidoneThe risk or severity of adverse effects can be increased when Clemastine is combined with Primidone.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Clemastine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Clemastine.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Clemastine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clemastine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Clemastine.
ProguanilThe metabolism of Proguanil can be decreased when combined with Clemastine.
PromazineThe metabolism of Promazine can be decreased when combined with Clemastine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Clemastine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Clemastine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Clemastine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Clemastine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine.
PropofolThe metabolism of Propofol can be decreased when combined with Clemastine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clemastine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Clemastine.
PropranololThe metabolism of Propranolol can be decreased when combined with Clemastine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Clemastine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clemastine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Clemastine.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Clemastine.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Clemastine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Clemastine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clemastine.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Clemastine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clemastine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Clemastine.
QuinidineThe metabolism of Quinidine can be decreased when combined with Clemastine.
QuinineThe metabolism of Quinine can be decreased when combined with Clemastine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Clemastine.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Clemastine.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Clemastine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Clemastine.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Clemastine.
RanolazineThe metabolism of Ranolazine can be decreased when combined with Clemastine.
RasagilineRasagiline may increase the anticholinergic activities of Clemastine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Clemastine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Clemastine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clemastine.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Clemastine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clemastine.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Clemastine.
repinotanThe metabolism of repinotan can be decreased when combined with Clemastine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clemastine.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Clemastine.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Clemastine.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Clemastine.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Clemastine.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Clemastine.
RiociguatThe metabolism of Riociguat can be decreased when combined with Clemastine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Clemastine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Clemastine.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Clemastine.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Clemastine.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Clemastine.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Clemastine.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Clemastine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Clemastine.
RopiniroleClemastine may increase the sedative activities of Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Clemastine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clemastine.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Clemastine.
RotigotineClemastine may increase the sedative activities of Rotigotine.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Clemastine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clemastine.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Clemastine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clemastine.
SafrazineSafrazine may increase the anticholinergic activities of Clemastine.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Clemastine.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Clemastine.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Clemastine.
ScopolamineThe risk or severity of adverse effects can be increased when Clemastine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clemastine.
SelegilineSelegiline may increase the anticholinergic activities of Clemastine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Clemastine.
SelexipagThe metabolism of Selexipag can be decreased when combined with Clemastine.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Clemastine.
SertindoleThe metabolism of Sertindole can be decreased when combined with Clemastine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Clemastine.
SertralineThe risk or severity of adverse effects can be increased when Clemastine is combined with Sertraline.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Clemastine.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clemastine.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Clemastine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Clemastine.
SilodosinThe metabolism of Silodosin can be decreased when combined with Clemastine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Clemastine.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Clemastine.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Clemastine.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Clemastine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Clemastine.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Clemastine.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Clemastine.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Clemastine.
SparteineThe metabolism of Sparteine can be decreased when combined with Clemastine.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Clemastine.
StiripentolThe risk or severity of adverse effects can be increased when Clemastine is combined with Stiripentol.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Clemastine.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clemastine.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Clemastine.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Clemastine.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Clemastine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clemastine.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Clemastine.
SuvorexantThe risk or severity of adverse effects can be increased when Clemastine is combined with Suvorexant.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Clemastine.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Clemastine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Clemastine.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Clemastine.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Clemastine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Clemastine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Clemastine.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Clemastine.
TasimelteonThe risk or severity of adverse effects can be increased when Clemastine is combined with Tasimelteon.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Clemastine.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Clemastine.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Clemastine.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Clemastine.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Clemastine.
TemazepamThe metabolism of Temazepam can be decreased when combined with Clemastine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clemastine.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Clemastine.
TeniposideThe metabolism of Teniposide can be decreased when combined with Clemastine.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Clemastine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Clemastine.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Clemastine.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Clemastine.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Clemastine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Clemastine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clemastine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Clemastine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clemastine.
ThalidomideClemastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clemastine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Clemastine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clemastine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Clemastine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Clemastine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clemastine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Clemastine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clemastine.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Clemastine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Clemastine.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Clemastine.
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Clemastine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Clemastine.
TimololThe metabolism of Timolol can be decreased when combined with Clemastine.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Clemastine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Clemastine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Clemastine.
TizanidineThe risk or severity of adverse effects can be increased when Clemastine is combined with Tizanidine.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Clemastine.
TolcaponeThe risk or severity of adverse effects can be increased when Clemastine is combined with Tolcapone.
ToloxatoneToloxatone may increase the anticholinergic activities of Clemastine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Clemastine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Clemastine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Clemastine.
ToremifeneThe metabolism of Toremifene can be decreased when combined with Clemastine.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Clemastine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clemastine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clemastine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Clemastine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Clemastine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the anticholinergic activities of Clemastine.
TranylcypromineThe risk or severity of adverse effects can be increased when Clemastine is combined with Tranylcypromine.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Clemastine.
TrazodoneThe risk or severity of adverse effects can be increased when Clemastine is combined with Trazodone.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Clemastine.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Clemastine.
TriazolamThe metabolism of Triazolam can be decreased when combined with Clemastine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clemastine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clemastine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clemastine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Clemastine.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Clemastine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Clemastine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clemastine.
TriprolidineThe risk or severity of adverse effects can be increased when Clemastine is combined with Triprolidine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Clemastine.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Clemastine.
UdenafilThe metabolism of Udenafil can be decreased when combined with Clemastine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Clemastine.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Clemastine.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Clemastine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clemastine.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Clemastine.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Clemastine.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Clemastine.
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Clemastine.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Clemastine.
VerapamilThe metabolism of Verapamil can be decreased when combined with Clemastine.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Clemastine.
VigabatrinThe risk or severity of adverse effects can be increased when Clemastine is combined with Vigabatrin.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Clemastine.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Clemastine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Clemastine.
VincristineThe metabolism of Vincristine can be decreased when combined with Clemastine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Clemastine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Clemastine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Clemastine.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Clemastine.
VortioxetineThe risk or severity of adverse effects can be increased when Clemastine is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be decreased when combined with Clemastine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Clemastine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Clemastine.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Clemastine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Clemastine.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Clemastine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clemastine.
ZiconotideThe risk or severity of adverse effects can be increased when Clemastine is combined with Ziconotide.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Clemastine.
ZileutonThe metabolism of Zileuton can be decreased when combined with Clemastine.
ZimelidineThe risk or severity of adverse effects can be increased when Clemastine is combined with Zimelidine.
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Clemastine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Clemastine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Clemastine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Clemastine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clemastine.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Clemastine.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Clemastine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clemastine.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Clemastine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Clemastine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Clemastine.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Clemastine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clemastine.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Taniguchi K, Urakami M, Takanaka K: [Effects of antiallergic agents on polymorphonuclear leukocytes. The inhibition of arachidonic acid release and superoxide production]. Nihon Yakurigaku Zasshi. 1987 Aug;90(2):97-103. [PubMed:2890562 ]
  3. Hallberg T, Dohlsten M, Baldetorp B: Demonstration of histamine receptors on human platelets by flow cytometry. Scand J Haematol. 1984 Feb;32(2):113-8. [PubMed:6701456 ]
  4. Dorsch W, Hintschich C, Neuhauser J, Weber J: Sequential histamine inhalations cause increased bronchial histamine reactivity in guinea pigs: role of platelets, thromboxanes and prostacyclin. Naunyn Schmiedebergs Arch Pharmacol. 1984 Sep;327(2):148-55. [PubMed:6387510 ]
  5. Taniguchi K, Masuda Y, Takanaka K: Inhibitory effects of histamine H1 receptor blocking drugs on metabolic activations of neutrophils. J Pharmacobiodyn. 1991 Feb;14(2):87-93. [PubMed:1678430 ]
  6. Oishi R, Shishido S, Yamori M, Saeki K: Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4. [PubMed:7513381 ]
  7. Thomas RH, Browne PD, Kirby JD: The influence of ranitidine, alone and in combination with clemastine, on histamine-mediated cutaneous weal and flare reactions in human skin. Br J Clin Pharmacol. 1985 Oct;20(4):377-82. [PubMed:4074605 ]
  8. Thomson NC, Kerr JW: Effect of inhaled H1 and H2 receptor antagonist in normal and asthmatic subjects. Thorax. 1980 Jun;35(6):428-34. [PubMed:6449094 ]
  9. Hayashi H, Okajima M, Yamada K: Atrial T (Ta) loop in dogs with or without atrial injury. Am Heart J. 1976 May;91(5):607-17. [PubMed:1266718 ]
  10. Schran HF, Petryk L, Chang CT, O'Connor R, Gelbert MB: The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol. 1996 Oct;36(10):911-22. [PubMed:8930778 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23